Overview

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Status:
Recruiting

Trial end date:
2024-07-12

Target enrollment:

Participant gender:

Summary

Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Fulvestrant